Playback speed
10 seconds
ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relapsed SCLC Receiving Single-Agent Lurbinectedin
By
ASCO 2022 Conference Coverage
FEATURING
Alejandro Navarro
By
ASCO 2022 Conference Coverage
FEATURING
Alejandro Navarro
245 views
June 15, 2022
Login to view comments.
Click here to Login